- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05062200
A Study of JNJ-77242113 in Healthy Japanese and Chinese Participants
November 22, 2022 updated by: Janssen Pharmaceutical K.K.
A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-77242113 in Healthy Japanese Participants and a Single Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-77242113 in Healthy Chinese Participants
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of JNJ-77242113 after single ascending oral dose administration as an immediate-release (IR) tablet formulation in healthy Japanese participants and after single oral dose administration as an IR tablet formulation in healthy Chinese participants; and as a delayed release (DR) tablet formulation in healthy Japanese participants.
Study Overview
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Fukuoka, Japan, 812-0025
- Souseikai Hakata Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- For Parts 1 and 3: Japanese male or female of non-childbearing potential, who have parents and maternal and paternal grandparents who are of Japanese ethnicity
- For Part 2: Chinese male or female of non-childbearing potential, who have parents and maternal and paternal grandparents who are of Chinese ethnicity
- Healthy on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening. If there are abnormalities, they must be consistent with the underlying illness in the study population. This determination must be recorded in the participant's source documents and initialed by the investigator
- Body weight not less than 50 kilograms (kg) and body mass index within the range 18 and 30 kilograms per meter square (kg/m^2) (inclusive)
- Blood pressure (after the participant is supine for 5 minutes) between 90 and 140 millimeters of mercury (mmHg) systolic, inclusive, and no higher than 90 mmHg diastolic. If blood pressure is out of range, up to 2 repeated assessments are permitted
Exclusion Criteria:
- History of malignancy before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, which is considered cured with minimal risk of recurrence)
- Known allergies, hypersensitivity, or intolerance to JNJ-77242113 or its excipients
- Use of a live vaccine within 30 days prior to screening or anticipated need for a live vaccine during the study or for 30 days following the dose of study drug
- Received an experimental drug (including investigational vaccines) or used an experimental medical device within 1 month or within a period less than 10 times the drug's half-life, whichever is longer, before the dose of the study intervention is scheduled
- Test positive for human immunodeficiency virus (HIV)-1 and 2 antigen/antibodies, test positive for hepatitis C antibodies, test positive for syphilis, or test positive for hepatitis B virus (HBV) infection at screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1: JNJ-77242113 or Placebo (Single Ascending Dose [SAD])
Japanese participants will receive single oral dose 1 of JNJ-77242113 (immediate-release [IR] tablet) or matching placebo on Day 1 in Cohort 1 of Part 1.
|
JNJ-77242113 will be administered as an oral tablet.
Matching placebo will be administered as an oral tablet.
|
Experimental: Cohort 2: JNJ-77242113 or Placebo (SAD)
Japanese participants will receive single oral dose 2 of JNJ-77242113 (IR tablet) or matching placebo on Day 1 in Cohort 2 of Part 1.
|
JNJ-77242113 will be administered as an oral tablet.
Matching placebo will be administered as an oral tablet.
|
Experimental: Cohort 3: JNJ-77242113 or Placebo (Single Dose [SD])
Chinese participants will receive single oral dose 2 of JNJ-77242113 (IR tablet) or matching placebo on Day 1 in Cohort 3 of Part 2.
|
JNJ-77242113 will be administered as an oral tablet.
Matching placebo will be administered as an oral tablet.
|
Experimental: Cohort 4: JNJ-77242113 or Placebo (SD)
Japanese participants will receive single oral dose 3 of JNJ-77242113 (delayed-release [DR] tablet) with absorption enhancer (AbE) or matching placebo on Day 1 in Cohort 4 of Part 3.
|
JNJ-77242113 will be administered as an oral tablet.
Matching placebo will be administered as an oral tablet.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Parts 1, 2 and 3: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability
Time Frame: Up to 6 weeks
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.
|
Up to 6 weeks
|
Parts 1, 2 and 3: Plasma Concentration of JNJ-77242113
Time Frame: Predose up to 48 hours postdose (Up to Day 3)
|
Plasma samples will be analyzed to determine concentrations of JNJ-77242113 using a validated, specific and sensitive method.
|
Predose up to 48 hours postdose (Up to Day 3)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 25, 2021
Primary Completion (Actual)
September 28, 2022
Study Completion (Actual)
September 28, 2022
Study Registration Dates
First Submitted
September 21, 2021
First Submitted That Met QC Criteria
September 21, 2021
First Posted (Actual)
September 30, 2021
Study Record Updates
Last Update Posted (Actual)
November 23, 2022
Last Update Submitted That Met QC Criteria
November 22, 2022
Last Verified
November 1, 2022
More Information
Terms related to this study
Other Study ID Numbers
- CR109097
- 77242113PSO1002 (Other Identifier: Janssen Pharmaceutical K.K., Japan)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on JNJ-77242113
-
Janssen Pharmaceutical K.K.RecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Janssen Research & Development, LLCActive, not recruitingPlaque PsoriasisUnited States, Korea, Republic of, Germany, France, Taiwan, Japan, Spain, United Kingdom, Poland, Canada
-
Janssen Research & Development, LLCRecruitingColitis, UlcerativeKorea, Republic of, Canada, United States, Australia, Czechia, Malaysia, Germany, Turkey, Japan, Belgium, Hungary, Italy, Spain, China, Poland, United Kingdom, Brazil, France, Argentina, Romania, India
-
Janssen Research & Development, LLCActive, not recruitingPlaque PsoriasisUnited States, Korea, Republic of, Hungary, United Kingdom, Canada, Germany, Poland, Turkey, Taiwan, Spain, Argentina
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCActive, not recruitingPlaque PsoriasisGermany, United States, Hungary, Italy, Turkey, Korea, Republic of, United Kingdom, China, Taiwan, Poland, Canada, France, Australia, Spain, Argentina, Japan
-
Janssen Research & Development, LLCCompletedPlaque PsoriasisUnited States, Canada, Germany, France, Spain, Poland
-
Janssen Research & Development, LLCRecruitingPlaque PsoriasisUnited States, Korea, Republic of, Taiwan, Germany, Poland, Brazil, Spain, Hungary, Australia, Canada, Romania
-
Janssen Research & Development, LLCRecruitingPlaque PsoriasisKorea, Republic of, United Kingdom, United States, Poland, Germany, Brazil, Spain, Taiwan, Hungary, Japan, Canada, Argentina, Australia
-
Janssen Research & Development, LLCCompletedPlaque PsoriasisUnited States, Korea, Republic of, Germany, France, Canada, Japan, Taiwan, Spain, United Kingdom, Poland